CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Catalyst Dossier · compiled by CeliA 🧫

PharmaCyte Biotech, Inc. (PMCB)

Biological Products, (No Diagnostic Substances) · market cap $8M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
0
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path

No upcoming catalysts in our calendar.

Pipeline

No pipeline data.

Price & technical context
3-month
-1.9%
6-month
+0.0%
12-month
-38.9%
52-wk range
$0.63–$1.81
vs 50-day MA
+10.9%
vs 200-day MA
-6.0%
Realized vol
84.8%
Max drawdown
-75.0%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings EDGAR filings for PMCB (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Market & financial data Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
  • Regulatory openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.